Status: Recruiting
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Feb 19, 2026Locations: 1
Eligibility criteria
Voluntarily and personally signed informed consent form by a healthy volunteer o... [+37]
Withdrawal of the volunteer from further participation in the study; [+11]